Human Papillomavirus (HPV) Prevalence in Urine Samples From 17-Year-Old Norwegian Girls Born in 1997, by HPV Vaccination Status (N = 6225)
| HPV Type . | Unvaccinateda (n = 1321) . | Fully Vaccinatedb (n = 4904) . | ||||
|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | RR . | No. . | % (95% CI) . | RR (95% CI) . | |
| Any HPV type | 141 | 10.7 (9.1–12.5) | 1 (ref) | 573 | 11.7 (10.8–12.6) | 1.09 (.92–1.30) |
| Any HR typec | 62 | 4.7 (3.7–6.0) | 1 (ref) | 244 | 5.0 (4.4–5.6) | 1.06 (.81–1.39) |
| Any probably/possibly HR typed | 30 | 2.3 (1.6–3.2) | 1 (ref) | 153 | 3.1 (2.7–3.6) | 1.37 (.94–2.02) |
| Any LR typee | 69 | 5.2 (4.1–6.6) | 1 (ref) | 288 | 5.9 (5.2–6.6) | 1.12 (.87–1.45) |
| Vaccine types | ||||||
| Vaccine typesf | 46 | 3.5 (2.6–4.6) | 1 (ref) | 39 | 0.8 (.6–1.1) | 0.23 (.15–.35) |
| HPV-16 or -18 | 35 | 2.6 (1.9–3.7) | 1 (ref) | 35 | 0.7 (.5–1.0) | 0.27 (.17–.43) |
| HPV-6 or -11 | 14 | 1.1 (.6–1.8) | 1 (ref) | 5 | 0.1 (.04–.2) | 0.10 (.04–.26) |
| HPV-6 | 12 | 0.9 (.5–1.6) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.09 (.03–.26) |
| HPV-11 | 2 | 0.2 (.04–.6) | 1 (ref) | 1 | 0.02 (.004–.1) | 0.13 (.02–1.03) |
| HPV-16 | 24 | 1.8 (1.2–2.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 0.35 (.21–.59) |
| HPV-18 | 11 | 0.8 (.5–1.5) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.10 (.03–.29) |
| Nonvaccine types | ||||||
| Any nonvaccine HR type | 40 | 3.0 (2.2–4.1) | 1 (ref) | 210 | 4.3 (3.8–4.9) | 1.41 (1.02–1.97) |
| Any HR type other than 16, 18, 31, 33, and 45 | 34 | 2.6 (1.8–3.6) | 1 (ref) | 189 | 3.9 (3.4–4.4) | 1.50 (1.05–2.14) |
| HPV-31, -33, -45, -52, or 58 | 16 | 1.2 (.7–2.0) | 1 (ref) | 80 | 1.6 (1.3–2.0) | 1.35 (.80–2.28) |
| HPV-31, -33, or -45 | 13 | 1.0 (.6–1.7) | 1 (ref) | 42 | 0.9 (.6–1.2) | 0.87 (.47–1.60) |
| HPV-31 | 8 | 0.6 (.3–1.2) | 1 (ref) | 7 | 0.1 (.07–.3) | 0.24 (.09–.62) |
| HPV-33 | 2 | 0.2 (.04–.6) | 1 (ref) | 23 | 0.5 (.3–.7) | 3.1 (.81–11.85) |
| HPV-35 | 0 | 0 (0–.3) | 1 (ref) | 16 | 0.3 (.2–.5) | … |
| HPV-39 | 6 | 0.5 (.2–1.0) | 1 (ref) | 22 | 0.4 (.3–.7) | 0.99 (.41–2.37) |
| HPV-45 | 4 | 0.3 (.1–.8) | 1 (ref) | 13 | 0.3 (.2–.5) | 0.88 (.30–2.55) |
| HPV-51 | 10 | 0.8 (.4–1.4) | 1 (ref) | 61 | 1.2 (1.0–1.6) | 1.64 (.86–3.16) |
| HPV-52 | 3 | 0.2 (.08–.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 2.78 (.91–8.57) |
| HPV-56 | 11 | 0.8 (.5–1.5) | 1 (ref) | 46 | 0.9 (.7–1.2) | 1.13 (.59–2.15) |
| HPV-58 | 1 | 0.08 (.01–.4) | 1 (ref) | 12 | 0.2 (.1–.4) | 3.23 (.54–19.37) |
| HPV-59 | 9 | 0.7 (.4–1.3) | 1 (ref) | 39 | 0.8 (.6–1.1) | 1.17 (.58–2.37) |
| Other | ||||||
| Nonavalent HPV typesg | 56 | 4.2 (3.3–5.5) | 1 (ref) | 119 | 2.4 (2.0–2.9) | 0.57 (.42–.78) |
| HPV Type . | Unvaccinateda (n = 1321) . | Fully Vaccinatedb (n = 4904) . | ||||
|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | RR . | No. . | % (95% CI) . | RR (95% CI) . | |
| Any HPV type | 141 | 10.7 (9.1–12.5) | 1 (ref) | 573 | 11.7 (10.8–12.6) | 1.09 (.92–1.30) |
| Any HR typec | 62 | 4.7 (3.7–6.0) | 1 (ref) | 244 | 5.0 (4.4–5.6) | 1.06 (.81–1.39) |
| Any probably/possibly HR typed | 30 | 2.3 (1.6–3.2) | 1 (ref) | 153 | 3.1 (2.7–3.6) | 1.37 (.94–2.02) |
| Any LR typee | 69 | 5.2 (4.1–6.6) | 1 (ref) | 288 | 5.9 (5.2–6.6) | 1.12 (.87–1.45) |
| Vaccine types | ||||||
| Vaccine typesf | 46 | 3.5 (2.6–4.6) | 1 (ref) | 39 | 0.8 (.6–1.1) | 0.23 (.15–.35) |
| HPV-16 or -18 | 35 | 2.6 (1.9–3.7) | 1 (ref) | 35 | 0.7 (.5–1.0) | 0.27 (.17–.43) |
| HPV-6 or -11 | 14 | 1.1 (.6–1.8) | 1 (ref) | 5 | 0.1 (.04–.2) | 0.10 (.04–.26) |
| HPV-6 | 12 | 0.9 (.5–1.6) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.09 (.03–.26) |
| HPV-11 | 2 | 0.2 (.04–.6) | 1 (ref) | 1 | 0.02 (.004–.1) | 0.13 (.02–1.03) |
| HPV-16 | 24 | 1.8 (1.2–2.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 0.35 (.21–.59) |
| HPV-18 | 11 | 0.8 (.5–1.5) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.10 (.03–.29) |
| Nonvaccine types | ||||||
| Any nonvaccine HR type | 40 | 3.0 (2.2–4.1) | 1 (ref) | 210 | 4.3 (3.8–4.9) | 1.41 (1.02–1.97) |
| Any HR type other than 16, 18, 31, 33, and 45 | 34 | 2.6 (1.8–3.6) | 1 (ref) | 189 | 3.9 (3.4–4.4) | 1.50 (1.05–2.14) |
| HPV-31, -33, -45, -52, or 58 | 16 | 1.2 (.7–2.0) | 1 (ref) | 80 | 1.6 (1.3–2.0) | 1.35 (.80–2.28) |
| HPV-31, -33, or -45 | 13 | 1.0 (.6–1.7) | 1 (ref) | 42 | 0.9 (.6–1.2) | 0.87 (.47–1.60) |
| HPV-31 | 8 | 0.6 (.3–1.2) | 1 (ref) | 7 | 0.1 (.07–.3) | 0.24 (.09–.62) |
| HPV-33 | 2 | 0.2 (.04–.6) | 1 (ref) | 23 | 0.5 (.3–.7) | 3.1 (.81–11.85) |
| HPV-35 | 0 | 0 (0–.3) | 1 (ref) | 16 | 0.3 (.2–.5) | … |
| HPV-39 | 6 | 0.5 (.2–1.0) | 1 (ref) | 22 | 0.4 (.3–.7) | 0.99 (.41–2.37) |
| HPV-45 | 4 | 0.3 (.1–.8) | 1 (ref) | 13 | 0.3 (.2–.5) | 0.88 (.30–2.55) |
| HPV-51 | 10 | 0.8 (.4–1.4) | 1 (ref) | 61 | 1.2 (1.0–1.6) | 1.64 (.86–3.16) |
| HPV-52 | 3 | 0.2 (.08–.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 2.78 (.91–8.57) |
| HPV-56 | 11 | 0.8 (.5–1.5) | 1 (ref) | 46 | 0.9 (.7–1.2) | 1.13 (.59–2.15) |
| HPV-58 | 1 | 0.08 (.01–.4) | 1 (ref) | 12 | 0.2 (.1–.4) | 3.23 (.54–19.37) |
| HPV-59 | 9 | 0.7 (.4–1.3) | 1 (ref) | 39 | 0.8 (.6–1.1) | 1.17 (.58–2.37) |
| Other | ||||||
| Nonavalent HPV typesg | 56 | 4.2 (3.3–5.5) | 1 (ref) | 119 | 2.4 (2.0–2.9) | 0.57 (.42–.78) |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; LR, low risk; RR, relative risk.
aReceived no doses of HPV vaccine 15 days before sampling
bReceived 3 doses of HPV vaccine at least 15 days before sampling
cHPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.
dHPV type 26, 30, 53, 66, 67, 68, 69, 70, 73, or 82.
eHPV type 6, 11, 40, 42, 43, 54, 61, 74, 81, 83, 86, 87, 89, 90, or 91.
fHPV type 6, 11, 16, or 18.
gHPV type 6, 11, 16, 18, 31, 33, 45, 52, or 58.
Human Papillomavirus (HPV) Prevalence in Urine Samples From 17-Year-Old Norwegian Girls Born in 1997, by HPV Vaccination Status (N = 6225)
| HPV Type . | Unvaccinateda (n = 1321) . | Fully Vaccinatedb (n = 4904) . | ||||
|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | RR . | No. . | % (95% CI) . | RR (95% CI) . | |
| Any HPV type | 141 | 10.7 (9.1–12.5) | 1 (ref) | 573 | 11.7 (10.8–12.6) | 1.09 (.92–1.30) |
| Any HR typec | 62 | 4.7 (3.7–6.0) | 1 (ref) | 244 | 5.0 (4.4–5.6) | 1.06 (.81–1.39) |
| Any probably/possibly HR typed | 30 | 2.3 (1.6–3.2) | 1 (ref) | 153 | 3.1 (2.7–3.6) | 1.37 (.94–2.02) |
| Any LR typee | 69 | 5.2 (4.1–6.6) | 1 (ref) | 288 | 5.9 (5.2–6.6) | 1.12 (.87–1.45) |
| Vaccine types | ||||||
| Vaccine typesf | 46 | 3.5 (2.6–4.6) | 1 (ref) | 39 | 0.8 (.6–1.1) | 0.23 (.15–.35) |
| HPV-16 or -18 | 35 | 2.6 (1.9–3.7) | 1 (ref) | 35 | 0.7 (.5–1.0) | 0.27 (.17–.43) |
| HPV-6 or -11 | 14 | 1.1 (.6–1.8) | 1 (ref) | 5 | 0.1 (.04–.2) | 0.10 (.04–.26) |
| HPV-6 | 12 | 0.9 (.5–1.6) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.09 (.03–.26) |
| HPV-11 | 2 | 0.2 (.04–.6) | 1 (ref) | 1 | 0.02 (.004–.1) | 0.13 (.02–1.03) |
| HPV-16 | 24 | 1.8 (1.2–2.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 0.35 (.21–.59) |
| HPV-18 | 11 | 0.8 (.5–1.5) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.10 (.03–.29) |
| Nonvaccine types | ||||||
| Any nonvaccine HR type | 40 | 3.0 (2.2–4.1) | 1 (ref) | 210 | 4.3 (3.8–4.9) | 1.41 (1.02–1.97) |
| Any HR type other than 16, 18, 31, 33, and 45 | 34 | 2.6 (1.8–3.6) | 1 (ref) | 189 | 3.9 (3.4–4.4) | 1.50 (1.05–2.14) |
| HPV-31, -33, -45, -52, or 58 | 16 | 1.2 (.7–2.0) | 1 (ref) | 80 | 1.6 (1.3–2.0) | 1.35 (.80–2.28) |
| HPV-31, -33, or -45 | 13 | 1.0 (.6–1.7) | 1 (ref) | 42 | 0.9 (.6–1.2) | 0.87 (.47–1.60) |
| HPV-31 | 8 | 0.6 (.3–1.2) | 1 (ref) | 7 | 0.1 (.07–.3) | 0.24 (.09–.62) |
| HPV-33 | 2 | 0.2 (.04–.6) | 1 (ref) | 23 | 0.5 (.3–.7) | 3.1 (.81–11.85) |
| HPV-35 | 0 | 0 (0–.3) | 1 (ref) | 16 | 0.3 (.2–.5) | … |
| HPV-39 | 6 | 0.5 (.2–1.0) | 1 (ref) | 22 | 0.4 (.3–.7) | 0.99 (.41–2.37) |
| HPV-45 | 4 | 0.3 (.1–.8) | 1 (ref) | 13 | 0.3 (.2–.5) | 0.88 (.30–2.55) |
| HPV-51 | 10 | 0.8 (.4–1.4) | 1 (ref) | 61 | 1.2 (1.0–1.6) | 1.64 (.86–3.16) |
| HPV-52 | 3 | 0.2 (.08–.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 2.78 (.91–8.57) |
| HPV-56 | 11 | 0.8 (.5–1.5) | 1 (ref) | 46 | 0.9 (.7–1.2) | 1.13 (.59–2.15) |
| HPV-58 | 1 | 0.08 (.01–.4) | 1 (ref) | 12 | 0.2 (.1–.4) | 3.23 (.54–19.37) |
| HPV-59 | 9 | 0.7 (.4–1.3) | 1 (ref) | 39 | 0.8 (.6–1.1) | 1.17 (.58–2.37) |
| Other | ||||||
| Nonavalent HPV typesg | 56 | 4.2 (3.3–5.5) | 1 (ref) | 119 | 2.4 (2.0–2.9) | 0.57 (.42–.78) |
| HPV Type . | Unvaccinateda (n = 1321) . | Fully Vaccinatedb (n = 4904) . | ||||
|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | RR . | No. . | % (95% CI) . | RR (95% CI) . | |
| Any HPV type | 141 | 10.7 (9.1–12.5) | 1 (ref) | 573 | 11.7 (10.8–12.6) | 1.09 (.92–1.30) |
| Any HR typec | 62 | 4.7 (3.7–6.0) | 1 (ref) | 244 | 5.0 (4.4–5.6) | 1.06 (.81–1.39) |
| Any probably/possibly HR typed | 30 | 2.3 (1.6–3.2) | 1 (ref) | 153 | 3.1 (2.7–3.6) | 1.37 (.94–2.02) |
| Any LR typee | 69 | 5.2 (4.1–6.6) | 1 (ref) | 288 | 5.9 (5.2–6.6) | 1.12 (.87–1.45) |
| Vaccine types | ||||||
| Vaccine typesf | 46 | 3.5 (2.6–4.6) | 1 (ref) | 39 | 0.8 (.6–1.1) | 0.23 (.15–.35) |
| HPV-16 or -18 | 35 | 2.6 (1.9–3.7) | 1 (ref) | 35 | 0.7 (.5–1.0) | 0.27 (.17–.43) |
| HPV-6 or -11 | 14 | 1.1 (.6–1.8) | 1 (ref) | 5 | 0.1 (.04–.2) | 0.10 (.04–.26) |
| HPV-6 | 12 | 0.9 (.5–1.6) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.09 (.03–.26) |
| HPV-11 | 2 | 0.2 (.04–.6) | 1 (ref) | 1 | 0.02 (.004–.1) | 0.13 (.02–1.03) |
| HPV-16 | 24 | 1.8 (1.2–2.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 0.35 (.21–.59) |
| HPV-18 | 11 | 0.8 (.5–1.5) | 1 (ref) | 4 | 0.08 (.03–.2) | 0.10 (.03–.29) |
| Nonvaccine types | ||||||
| Any nonvaccine HR type | 40 | 3.0 (2.2–4.1) | 1 (ref) | 210 | 4.3 (3.8–4.9) | 1.41 (1.02–1.97) |
| Any HR type other than 16, 18, 31, 33, and 45 | 34 | 2.6 (1.8–3.6) | 1 (ref) | 189 | 3.9 (3.4–4.4) | 1.50 (1.05–2.14) |
| HPV-31, -33, -45, -52, or 58 | 16 | 1.2 (.7–2.0) | 1 (ref) | 80 | 1.6 (1.3–2.0) | 1.35 (.80–2.28) |
| HPV-31, -33, or -45 | 13 | 1.0 (.6–1.7) | 1 (ref) | 42 | 0.9 (.6–1.2) | 0.87 (.47–1.60) |
| HPV-31 | 8 | 0.6 (.3–1.2) | 1 (ref) | 7 | 0.1 (.07–.3) | 0.24 (.09–.62) |
| HPV-33 | 2 | 0.2 (.04–.6) | 1 (ref) | 23 | 0.5 (.3–.7) | 3.1 (.81–11.85) |
| HPV-35 | 0 | 0 (0–.3) | 1 (ref) | 16 | 0.3 (.2–.5) | … |
| HPV-39 | 6 | 0.5 (.2–1.0) | 1 (ref) | 22 | 0.4 (.3–.7) | 0.99 (.41–2.37) |
| HPV-45 | 4 | 0.3 (.1–.8) | 1 (ref) | 13 | 0.3 (.2–.5) | 0.88 (.30–2.55) |
| HPV-51 | 10 | 0.8 (.4–1.4) | 1 (ref) | 61 | 1.2 (1.0–1.6) | 1.64 (.86–3.16) |
| HPV-52 | 3 | 0.2 (.08–.7) | 1 (ref) | 31 | 0.6 (.4–.9) | 2.78 (.91–8.57) |
| HPV-56 | 11 | 0.8 (.5–1.5) | 1 (ref) | 46 | 0.9 (.7–1.2) | 1.13 (.59–2.15) |
| HPV-58 | 1 | 0.08 (.01–.4) | 1 (ref) | 12 | 0.2 (.1–.4) | 3.23 (.54–19.37) |
| HPV-59 | 9 | 0.7 (.4–1.3) | 1 (ref) | 39 | 0.8 (.6–1.1) | 1.17 (.58–2.37) |
| Other | ||||||
| Nonavalent HPV typesg | 56 | 4.2 (3.3–5.5) | 1 (ref) | 119 | 2.4 (2.0–2.9) | 0.57 (.42–.78) |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; LR, low risk; RR, relative risk.
aReceived no doses of HPV vaccine 15 days before sampling
bReceived 3 doses of HPV vaccine at least 15 days before sampling
cHPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.
dHPV type 26, 30, 53, 66, 67, 68, 69, 70, 73, or 82.
eHPV type 6, 11, 40, 42, 43, 54, 61, 74, 81, 83, 86, 87, 89, 90, or 91.
fHPV type 6, 11, 16, or 18.
gHPV type 6, 11, 16, 18, 31, 33, 45, 52, or 58.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
